Gene Therapy & AAV Engineering

Adeno-associated virus (AAV) vectors have emerged as one of the leading platforms for in vivo gene delivery, enabling the development of transformative therapies for genetic diseases. However, widespread clinical adoption remains constrained by manufacturing challenges, including low vector yields, inefficient genome packaging, producer cell stress, and high production costs.

Our research seeks to address these challenges by understanding and engineering the biological systems that drive AAV production. We investigate interactions between viral components and host cells to uncover factors that influence vector productivity, quality, and scalability. Through approaches spanning host cell engineering, systems biology, protein engineering, and high-throughput screening, we identify opportunities to improve manufacturing performance and develop more efficient production platforms. Ultimately, our goal is to advance the technologies needed to make gene therapies more accessible, reliable, and scalable for clinical applications.